
TCON
Healthcare · Biotechnology · $109,725 market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2024
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2024 | After the close | -1.05 | -0.94 | +10.5% |
| May 14, 2024 | After the close | -1.18 | -1.33 | -12.7% |
| Mar 5, 2024 | After the close | -0.08 | 0.01 | +112.5% |
| Nov 9, 2023 | After the close | 8.60 | 5.80 | -32.6% |
| Aug 14, 2023 | After the close | 2.30 | -4.00 | -273.9% |
| May 10, 2023 | After the close | -0.26 | -0.36 | -38.5% |
| Mar 8, 2023 | After the close | -5.10 | -6.20 | -21.6% |
| Nov 14, 2022 | After the close | -5.80 | -6.00 | -3.4% |
| Aug 10, 2022 | After the close | -7.90 | -6.20 | +21.5% |
| May 11, 2022 | After the close | -0.42 | -0.48 | -14.3% |
| Mar 15, 2022 | After the close | -7.10 | -8.00 | -12.7% |
| Nov 3, 2021 | After the close | -6.48 | -7.60 | -17.3% |
| Aug 11, 2021 | After the close | -6.24 |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal…
| -11.60 |
| -85.9% |
| May 5, 2021 | After the close | -6.05 | -6.60 | -9.1% |
| Feb 25, 2021 | After the close | -0.41 | -0.31 | +24.4% |
| Nov 10, 2020 | After the close | -13.25 | -7.60 | +42.6% |
| Aug 5, 2020 | After the close | -14.53 | -14.00 | +3.6% |
| May 13, 2020 | After the close | -22.65 | -15.60 | +31.1% |
| Feb 27, 2020 | After the close | -1.66 | -1.25 | +24.7% |
| Nov 5, 2019 | After the close | -41.00 | -34.00 | +17.1% |
| Aug 7, 2019 | After the close | -38.00 | -42.00 | -10.5% |
| May 14, 2019 | After the close | -42.00 | -48.00 | -14.3% |
| Feb 28, 2019 | After the close | -3.40 | -2.60 | +23.5% |
| Nov 7, 2018 | After the close | -56.50 | -60.00 | -6.2% |
| Aug 8, 2018 | After the close | -61.50 | -66.00 | -7.3% |
| May 9, 2018 | After the close | -72.00 | -92.00 | -27.8% |
| Feb 28, 2018 | After the close | -4.55 | -3.70 | +18.7% |